Bio-Techne's EBIT per Share for the
three
months ended in Dec. 2023 was $0.24.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.65.
During the past 12 months, the average EBIT per Share Growth Rate of Bio-Techne was -10.80% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 24.00% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 15.70% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bio-Techne's EBIT per Share or its related term are showing as below:
TECH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -3.3 Med: 18.85 Max: 83.7
Current: 24
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bio-Techne was 83.70% per year. The lowest was -3.30% per year. And the median was 18.85% per year.
TECH's 3-Year EBIT Growth Rate is ranked better than 75.56% of 1301
companies
in the Biotechnology industry
Industry Median: 3.5
vs TECH: 24.00
Bio-Techne's EBIT for the
three
months ended in Dec. 2023 was $38 Mil.
Bio-Techne EBIT per Share Historical Data
The historical data trend for Bio-Techne's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Bio-Techne Annual Data
Trend
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Jun22
Jun23
EBIT per Share
0.86
1.88
1.00
1.91
2.16
Bio-Techne Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EBIT per Share
0.43
0.51
0.57
0.34
0.24
Bio-Techne EBIT per Share Calculation
EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.
Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.
Bio-Techne's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (NAS:TECH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bio-Techne EBIT per Share Related Terms
Thank you for viewing the detailed overview of Bio-Techne's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 